Beta amyloid 42/40 is a biomarker for cerebral beta amyloid pathology1. A low beta amyloid 42/40 ratio reflects selective depletion of beta amyloid 42 due to the deposition in amyloid plaques in the brain. A low 42/40 ratio can also be due to amyloid deposition in the blood vessels due to cerebral amyloid angiopathy.
Test code(s): 11786, 12563, 13825, 13690, 94627, 94628, 92433, 10642
- Quest AD-Detect® Beta-Amyloid 42/40 Ratio, Plasma (11786)
- Quest AD-Detect® Apolipoprotein E (ApoE) Isoform, Plasma (12563)
- Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma (13825)
- Quest AD-Detect® Phosphorylated tau181 (p-tau181), Plasma (13690)
- Neurofilament Light Chain, Plasma (13979)
- Beta-Amyloid 42/40 Ratio, CSF (94627)
- Beta-Amyloid 42/40 Ratio and Apolipoprotein E (ApoE) Isoform Panel, CSF (94628)
- ADmark® Phospho-Tau/Total-Tau/A Beta42, Analysis and Interp, CSF (Symptomatic) (92433)
- ADmark® ApoE Genotype Analysis and Interpretation (Symptomatic) (10642)
- Quest AD-Detect® Beta-Amyloid 42/40 Ratio, Plasma (11786)
- Quest AD-Detect® Apolipoprotein E (ApoE) Isoform, Plasma (12563)
- Beta-Amyloid 42/40 Ratio, CSF (94627)
- Beta-Amyloid 42/40 Ratio and Apolipoprotein E (ApoE) Isoform Panel, CSF (94628)
- ADmark® Phospho-Tau/Total-Tau/A Beta42, Analysis and Interp, CSF (Symptomatic) (92433)
The combination of beta amyloid 42/40 and p-tau181 are utilized to detect AD pathology changes (amyloid plaques and neurofibrillary tangles) characteristic of Alzheimer’s disease. The presence of beta amyloid in the absence of a positive p-tau181 result typically occurs early in the Alzheimer’s disease continuum.
A beta amyloid ratio below 0.160 indicates a higher likelihood of having a positive amyloid PET scan. In a memory clinic cohort, a beta amyloid ratio of 0.169 to 0.160 correlated with 15% of patients having a positive amyloid PET scan, while a ratio of 0.159 to 0.150 correlated with an 85% chance of patients having a positive amyloid PET scan1.
The presence of APOE e4, particularly in patients who are homozygotes, indicates an increased risk for the development of ARIA with anti-amyloid treatment2.
A borderline CSF result typically is the result of a patient with underlying amyloid pathology, but the test result is more consistent with having mild cognitive impairment (MCI) rather than with full-blown Alzheimer’s disease3.
Patients with a positive beta amyloid 42/40 ratio and a negative PET scan are often earlier in the disease continuum. A recent study showed that patients with a positive 42/40 ratio and a negative PET scan are consistent with AD pathology on MRI4.
References
- Weber DM, Taylor SW, Lagier RJ et al. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment. Frontiers in Neurology. 2024;15:1364658. doi: 10.3389/fneur.2024.1364658
- Sperling RA, Jack CR, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-385. doi:10.1016/j.jalz.2011.05.2351
- Reimand J, Boon BDC, Collij LE, et al. Amyloid-beta PET and CSF in an autopsy-confirmed cohort. Ann Clin Trans Neurol. 7(11):2150-2160. doi:10.1002/acn3.51195
- DeSimone JC, Wang WE, Lowenstein DA, et al. Diffusion MRI relates to plasma Abeta42/40 in PET negative participants without dementia. Alzheimers Dement. 2024;20(4):2830-2842. doi:10.1002/alz.13693
This FAQ is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on the physician’s education, clinical expertise, and assessment of the patient.
Document FAQS.303 Version: 0
Version 0 effective 08/28/2024 to present
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.